Microbiota restoration therapy (MRT) compositions and methods of manufacture
Microbiota restoration therapy (MRT) compositions (e.g., oral MRT compositions) and methods for manufacturing MRT compositions are disclosed. An example method for manufacturing an MRT composition may include collecting a stool sample, purifying the stool sample to form a purified sample, stabilizing the purified sample to form a stabilized sample, converting the stabilized sample to a solid, adding one or more additives and/or excipients to the solid to form a treatment composition, and encapsulating the treatment composition.
1. An oral pharmaceutical product, comprising:
a blister package;
a capsule disposed within the blister package; and
a lyophilized material disposed within the capsule, the lyophilized material comprising fecal microbiota, polyethylene glycol, trehalose, sucrose, and glycerin,
wherein the fecal microbiota includes viable Bacteroides bacteria.
2. The oral pharmaceutical product of claim 1 , wherein the fecal microbiota includes at least 4.5×10 8 colony forming units (CFU) of bacteria, as assessed on CDC Anaerobic Blood Agar plates.
3. The oral pharmaceutical product of claim 1 , wherein the fecal microbiota includes at least 6.7×10 9 colony forming units (CFU) of bacteria, as assessed on CDC Anaerobic Blood Agar plates.
4. The oral pharmaceutical product of claim 1 , wherein the lyophilized material includes 1-10% polyethylene glycol.
5. The oral pharmaceutical product of claim 1 , wherein the lyophilized material includes 10-40% trehalose.
6. The oral pharmaceutical product of claim 1 , wherein the lyophilized material includes 10-40% sucrose.
7. The oral pharmaceutical product of claim 1 , wherein the lyophilized material includes 0.1-5% glycerin.
8. The oral pharmaceutical product of claim 1 , wherein the blister package further contains a desiccant.
9. The oral pharmaceutical product of claim 1 , wherein the capsule has a moisture content of 12% or less.
10. The oral pharmaceutical product of claim 1 , wherein the capsule has a moisture content of 4% or less.
11. The oral pharmaceutical product of claim 1 , wherein the capsule comprises a material selected from hypromellose, an anionic copolymer based on methacrylic acid and methyl methacrylate, hypromellose phthalate, hypromellose acetate succinate, and combinations thereof.
12. The oral pharmaceutical product of claim 1 , wherein the lyophilized material has a glass transition temperature of 30-75° C.
13. The oral pharmaceutical product of claim 1 , wherein the lyophilized material is stable at room temperature.
14. An oral pharmaceutical product, comprising:
a capsule; and
a lyophilized material disposed within the capsule, the lyophilized material comprising fecal microbiota and a lyophilization excipient;
wherein the lyophilization excipient includes polyethylene glycol; and
wherein the lyophilized material comprises viable Bacteroides bacteria.
15. The oral pharmaceutical product of claim 14 , wherein the capsule is disposed within a blister package.
16. The oral pharmaceutical product of claim 14 , wherein the capsule is disposed within a child-resistant container.
17. An oral pharmaceutical product, comprising:
a blister package;
one or more capsules disposed within the blister package; and
a lyophilized material disposed within each of the one or more capsules, the lyophilized material comprising fecal microbiota, polyethylene glycol, trehalose, sucrose, and glycerin,
wherein the fecal microbiota includes at least 4.5×10 8 colony forming units (CFU) of bacteria, as assessed on CDC Anaerobic Blood Agar plates.